ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2015
The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of Imaging Genetics in Alzheimer's Disease: A Systematic Review and Current Update.CNS & neurological disorders drug targets · 2024Pooled it
- Centralized Review of Alzheimer's Disease and Related Dementias Biomedical Repositories and Computational Methods.Bioengineering (Basel, Switzerland) · 2026Review
- The BRAIN Initiative data-sharing ecosystem: Characteristics, challenges, benefits, and opportunities.eLife · 2024Article
- The origins of ADNI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Data sharing as the foundation of discovery: ADNI and breakthroughs in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies.Clinical and translational science · 2023Review
- Deep phenotyping for precision medicine in Parkinson's disease.Disease models & mechanisms · 2022Article
- Imaging Biomarker Development for Lower Back Pain Using Machine Learning: How Image Analysis Can Help Back Pain.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The price of progress: Funding and financing Alzheimer's disease drug development.Alzheimer's & dementia (New York, N. Y.) · 2018Article
- Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.Neurology · 2017Article
- Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.Pharmaceutical research · 2017Review
- Accelerating drug development for Alzheimer's disease through the use of data standards.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the growing landscape of biomedical public-private-partnerships, particularly for Alzheimer's disease, the question is posed as to their value. What impacts do public-private-partnerships have on clinical and basic science research in Alzheimer's disease? The authors answer the question using the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a test case and example. ADNI is an exemplar of how public-private-partnerships can make an impact not only on clinical and basic science research and practice (including clinical trials), but also of how similar partnerships using ADNI as an example, can be designed to create a maximal impact within their fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.